

=> b reg
 FILE 'REGISTRY' ENTERED AT 13:04:01 ON 05 FEB 2010
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2010 HIGHEST RN 1204649-95-5
 DICTIONARY FILE UPDATES: 4 FEB 2010 HIGHEST RN 1204649-95-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l10
 L7 STR

Cy[^]Hy[^]Hy
 1 2 3

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS X6 C X1 N AT 1
 ECOUNT IS E3 C E2 N AT 2
 ECOUNT IS E4 C E1 O AT 3

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE
 L8 59880 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON OC4/ES AND N2C3/ES
 AND (C6 OR NC5)/ES
 L10 10904 SEA FILE=REGISTRY SUB=L8 SSS FUL L7

100.0% PROCESSED 59880 ITERATIONS 10904 ANSWERS
 SEARCH TIME: 00.00.05

=> d que sta l25
 L7 STR

Cy[^]Hy[^]Hy
 1 2 3


NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS X6 C X1 N AT 1
 ECOUNT IS E3 C E2 N AT 2
 ECOUNT IS E4 C E1 O AT 3

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE
 L8 59880 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON OC4/ES AND N2C3/ES
 AND (C6 OR NC5)/ES
 L10 10904 SEA FILE=REGISTRY SUB=L8 SSS FUL L7

L23

STR



```
REP G1=(0-7) C
VAR G2=8/9/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X6 C X1 N AT 1
ECOUNT IS E4 C E1 O AT 12
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

```
STEREO ATTRIBUTES: NONE
L25          496 SEA FILE=REGISTRY SUB=L10 SSS FUL L23
```

```
100.0% PROCESSED      10904 ITERATIONS                      496 ANSWERS
SEARCH TIME: 00.00.01
```

```
=> b zcap
FILE 'ZCAPLUS' ENTERED AT 13:04:11 ON 05 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 5 Feb 2010 VOL 152 ISS 7
FILE LAST UPDATED: 4 Feb 2010 (20100204/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d bib abs hitrn fhitr 129 tot
```

L29 ANSWER 1 OF 2 SCAPLUS COPYRIGHT 2010 ACS on SIN
AN 2004:841772 SCAPLUS
DN 141:350163

TI Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists.
IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 102 pp.
CODEN: GWXXBX

DT Patent
LA German
FAN_CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE-----10315572	A1	20041014	2003DE-100015572	20030405
AU-2004228120	A1	20041021	2004AU-000228120	20040308
CA-----2521201	A1	20041021	2004CA-002521201	20040308
WO-2004089931	A1	20041021	2004WO-EP0002353	20040308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CP, CU, CE, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HP, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SL, SS, TE, UG, ZM, ZW, AM, AZ, BF, BG, KG, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MD, MR, NE, SN, TD, TG				
EP-----1626967	A1	20060222	2004EP-000718277	20040308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR-2004009164	A	20060411	2004BR-00009164	20040308
CN-----1768051	A	20060503	2004CN-080008572	20040308
JP-2006522035	T	20060928	2006JP-000504584	20040308
US-20060264419	A1	20061123	2005US-000552065	20051005
ZA-2005008948	A	20070328	2005ZA-00008948	20051104
PRAI 2003DE-100015572	A	20030405		
2004WO-EP0002353	W	20040308		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L\$US DISPLAY FORMAT
OS MARPAT 141:350163
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R₁ = H, halo, (CH₂)_nHet, etc.; R₂ = (CH₂)_nHet, (CH₂)_nAr, cycloalkyl, etc.; R₃, R₄ = H, (CH₂)_nCO₂H, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted heterocycle; bicyclic-heterocycle and their pharmaceutically acceptable salts were prepared. For example, sodium triacetoxyborohydride mediated reductive amination of 1-methyl-piperazine and aldehyde II, e.g., prepared from 2-fluoro-α,γ-dioxo-hexenonebutanoic acid ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT_{2A} receptor binding assays, 167-examples of compds. I exhibited IC₅₀ values ranging from 0.015-4.7x10⁻⁷M. Compds. I are claimed suitable as ligands of 5-HT receptors.

TI 770739-06-5 770739-09-8 770739-77-0

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists.)

TI 770739-73-6P 770739-98-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists.)



PAGE 1-A

PAGE 2-A



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L29 ANSWER 2 OF 2 SCAPLUS COPYRIGHT 2010 ACS on SIN
AN 2004:841772 SCAPLUS
DN 141:352186


TI Preparation of arylpyrazoles as serotonin 5-HT_{2A} and/or 5-HT_{2C} receptor antagonists.

IN Schadt, Oliver; Arlt, Michael; Finsinger, Dirk; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 78 pp.
CODEN: GWXXBX

DT Patent
LA German
FAN_CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE-----10315569	A1	20041014	2003DE-100015569	20030405
AU-2004228124	A1	20041021	2004AU-000228124	20040310
CA-----2521227	A1	20041021	2004CA-002521227	20040310
WO-2004089932	A1	20041021	2004WO-EP0002453	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CP, CU, CE, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HP, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SL, SS, TE, UG, ZM, ZW, AM, AZ, BF, BG, KG, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MD, MR, NE, SN, TD, TG				
EP-----1611122	A1	20060104	2004EP-000718926	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CL, EE, HU, PL, SK				
BR-2004008986	A	20060328	2004BR-00008986	20040310
CN-----1768052	A	20060503	2004CN-080008603	20040310
JP-2006522039	T	20060928	2006JP-000504620	20040310
AT-----364601	T	20070715	2004AT-000718926	20040310
ES-----2287710	T3	20071216	2004ES-000718926	20040310
US-20070010531	A1	20070111	2005US-000552064	20051005
ZA-2005008923	A	20070228	2005ZA-00008923	20051103
PRAI 2003DE-100015569	A	20030405		
2004WO-EP0002453	W	20040310		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L\$US DISPLAY FORMAT
OS MARPAT 141:352186
GI



AB Title compds. I [I: R₁ = H, A, halo, (CH₂)_nAr, cycloalkyl, CF₃, NO₂, cyano, C(NH)NO₂, OCF₃; R₂ = (CH₂)_nHet, (CH₂)_nAr, cycloalkyl, CF₃; R₃, R₄ = H, (CH₂)_nCO₂H, (CH₂)_nCO₂H, (CH₂)_nCO₂H, (CH₂)_nHet, CH₂NO₂, etc.; R₅ = H, A; A = alkyl, alkoxy, alkenyl, alkoxymethyl; Ar = (substituted) Ph; Het = (aromatic) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; X = N, CH₂ with previous), were prepared. For example, [1-(4'-fluorophenyl)-3-furan-2-yl]-1-methyl-4-ylmethylmethyl (1-methylpyrrolidin-3-yl)amine showed 5-HT_{2A} activity with IC₅₀ = 5.14E-10.

TI 1054281-99-0 1054282-00-6 1054282-02-8
1054282-09-5 1054282-16-4 1054282-17-8
1054282-18-6 1054282-19-7 1054282-20-0
1054282-35-7 1054282-36-8 1054282-37-9
1054282-38-0 1054282-39-1 1054282-40-2
1054282-65-3 1054282-66-4 1054282-70-0
1054282-71-1 1054282-77-7 1054282-97-1
1054282-98-2 1054282-99-3 1054282-00-9


L29 ANSWER 2 OF 2 SCAPLUS COPYRIGHT 2010 ACS on SIN (Continued)

1054283-01-0	1054283-19-0	1054283-20-3
1054283-23-6	1054283-24-7	1054283-27-2
1054283-38-3	1054283-39-4	1054283-50-9
1054283-51-0	1054283-53-2	1054283-59-8
1054283-60-1	1054283-61-2	1054283-62-3
1054283-63-4	1054283-84-9	1054283-85-0
1054283-86-1	1054283-89-4	1054283-91-8
1054283-92-9	1054283-93-0	1054283-94-1
1054283-95-2	1054284-10-4	1054284-38-6
1054284-39-7	1054284-42-2	1054284-43-3
1054284-44-4	1054284-45-5	1054284-64-8
1054284-65-9	1054284-74-0	1054284-75-1
1054284-76-2	1054284-77-3	1054284-78-4
1054284-86-4	1054284-87-5	1054284-94-4
1054285-11-8	1054285-13-0	1054285-14-1
1054285-49-2	1054285-50-5	1054285-67-4
1054285-68-5	1054285-69-6	1054285-70-9
1054285-71-0	1054285-82-3	1054285-83-4
1054285-92-5	1054285-97-0	1054285-98-1
1054285-99-2	1054286-00-8	1054286-30-4
1054286-33-7	1054286-34-8	1054286-36-0
1054286-37-1	1054286-45-1	1054286-46-2
1054286-47-3	1054286-48-4	1054286-73-5
1054286-74-6	1054286-75-7	1054286-76-8
1054286-77-9		

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT_{2A} and/or 5-HT_{2C} receptor antagonists.)

TI 380652-94-8 770739-06-5 770739-07-6
770739-08-7 770739-09-8 770739-10-1
770739-11-2 770739-12-3 770739-13-4
770739-14-5 770739-15-6 770739-16-7
770739-17-8 770739-18-9 770739-19-0
770739-20-3 770739-21-4 770739-22-5
770739-23-6 770739-24-7 770739-26-9
770739-27-0 770739-28-1 770739-29-2
770739-30-5 770739-33-8 770739-34-9
770739-35-0 770739-36-1 770739-37-2
770739-38-3 770739-40-7 770739-42-9
770739-43-0 770739-44-1 770739-45-2
770739-46-3 770739-47-4 770739-48-5
770739-51-0 770739-54-3 770739-55-4
770739-56-5 770739-57-6 770739-58-7
770739-59-8 770739-61-2 770739-64-5
770739-65-6 770739-67-8 770739-68-9
770739-69-0 770739-70-3 770739-73-6
770739-75-8 770739-76-9 770739-77-0
770739-78-1 770739-79-2 770739-80-5
770739-82-7 770739-83-8 770739-85-0
770739-86-1 770739-88-3 770739-89-4
770739-90-7 770739-91-8 770739-94-1
770739-95-2 770739-96-3 770739-98-5
770740-02-8 770740-04-0 770740-05-1
770740-06-2 770740-08-4 770740-10-8
770740-11-9 770740-14-2 770740-15-3
770740-18-6 770740-19-7 770740-25-5
770740-27-7 770740-28-8 770740-29-9
770740-30-2 770740-34-6 770740-37-9
770740-39-1 770740-40-4 770740-42-6
770740-43-7 770740-44-8 770740-47-1
770740-49-2 770740-51-8 770740-52-8
770740-59-5 770740-60-8 770740-63-1
770740-64-2 770740-65-3 770740-67-5
770740-69-7 770740-70-0 771528-15-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Preparation of arylpyrazoles as serotonin 5-HT_{2A} and/or 5-HT_{2C} receptor antagonists.)
TI 1054281-99-0
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT_{2A} and/or 5-HT_{2C} receptor antagonists.)
RN 1054281-99-0 2CAPLUS
CN 1H-Pyrazole-4-ethanol, 1-(3'-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)-5-(2-

L29 ANSWER 2 OF 2 SCAPLUS COPYRIGHT 2010 ACS on SIN (Continued)
Furanyl)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> d bib abs hitstr 134 tot

L34 ANSWER 1 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2005:497502 ZCAPLUS
 DN 143:53440
 TI Substituted benzimidazole compounds as transcription factor-modulating
 compounds useful as anti-infectives
 IN Levy, Stuart B.; Aleksun, Michael N.; Podlogar, Brent L.; Ohneng, Kwasi;
 Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena; Bowser, Todd; Grier, Mark
 PA Paratek Pharmaceuticals, Inc., USA
 SO U.S. Pat. Appl. Publ., 463 pp., Cont.-in-part of U.S. Ser. No. 139,591.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20050124678	A1	20050609	2003US-000700661	20031103 <--
US-----7405235	B2	20080729		
CA-----2445515	A1	20021104	2002CA-002445515	20020506 <--
AU-2002367953	A1	20040106	2002AU-000367953	20020506 <--
AU-2002367953	B2	20080717		
EP-----1524974	A2	20050427	2002EP-000807554	20020506 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP-2005519998	T	20050707	2004JP-000515557	20020506 <--
US-20030229065	A1	20031211	2002US-000139591	20020814 <--
US-20040106553	A1	20040603	2003US-000602562	20030624 <--
US-20090131401	A1	20090521	2008US-000069723	20080212 <--
AU-20080203017	A1	20080731	2008AU-000203017	20080708 <--
PRAI 2001US-0028866P	P	20010504	<--	
2002US-000139591	A2	20020814	<--	
2002US-00423319P	P	20021101	<--	
2002US-00425916P	P	20021113	<--	
2002AU-000367953	A3	20020506	<--	
2002WO-US0014255	W	20020506	<--	
2002US-00391345P	P	20020624	<--	
2002US-00421218P	P	20021025	<--	
2002US-00429142P	P	20021126	<--	
2003US-00458935P	P	20030331	<--	
2003US-000700661	A3	20031103	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 143:53440


AB Substituted benzimidazole compds. useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzimidazole compds., as well as pharmaceutical preps. thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms. The present invention identifies microbial transcription factors, especially transcription factors of the AraC-XylS family, as virulence factors in microbes and shows that inhibition of these factors reduces the virulence of microbial cells. Because these transcription factors control virulence, rather than essential cellular processes, the development of resistance is much less likely.

634189-97-2

RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (substituted benzimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

RN 634189-97-2 ZCAPLUS
 CN Morpholine, 4-([4-(2-[5-(2-furanyl)-4,5-dihydro-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-4-thiazolyl)phenyl)sulfonyl]-, hydrobromide (1:1) (CA INDEX NAME)

L34 ANSWER 1 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



● HBr

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2004:841776 ZCAPLUS
 DN 141:350164
 TI Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor
 antagonists
 IN Schiemann, Kai; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd;
 Seyfried, Christof
 PA Merck Patent GmbH, Germany
 SO Ger. Offen., 17 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE-----10315573	A1	20041014	2003DE-100015573	20030405 <--
AU-2004228121	A1	20041021	2004AU-000228121	20040308 <--
CA-----2521202	A1	20041021	2004CA-002521202	20040308 <--
WO-2004089910	A1	20041021	2004WO-EP0002354	20040308 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, DE, DK, DM, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, ME, SD, SL, SZ, TE, UG, ZM, ZW, AM, AZ, BF, BG, KE, MD, RU, TJ, TM, AI, BE, BG, CH, CI, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG				
EP-----1611107	A1	20060104	2004EP-000718264	20040308 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR-2004009002	A	20060328	2004BR-00009002	20040308 <--
CN-----1768043	A	20060503	2004CN-080008629	20040308 <--
JP-2006522036	T	20060928	2006JP-000504585	20040308 <--
ZA-2005008951	A	20070328	2005ZA-00008951	20051104 <--
US-20070109871	A1	20070510	2006US-00051998	20061005 <--
US-----7566709	B2	20090728		
PRAI 2003DE-100015573	A	20030405	<--	
2004WO-EP0002354	W	20040308	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 141:350164

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Preparation of title compds. I [X = CH, N; Y = (CH₂)_m; m = 1-3; O = NR₃R₄,
 Het; R₁, R₂ = H, halo, (CH₂)_nhet, etc.; n = 0-5; R₃, R₄ = H, (CH₂)_nhet,
 cycloalkyl, etc.; n = 0-5; R₅ = A, Ar, Het; A = (un)substituted alkyl,
 alkoxy, alkenyl, etc.; Ar = (un)substituted aromatic; Het = organic heteroatom
 (sic)] and their pharmaceutically acceptable salts were prepared. For
 example, palladium mediated coupling of 4-fluorobenzeneboronic acid and
 phenylbromide II, e.g., prepared from 2-furylthianone in 3-steps, afforded
 arylpyrazole III. In 5-HT_{2A} receptor binding assays, compds. I exhibited
 nanomolar affinity (sic). Compds. I are claimed useful as ligands of 5-HT
 receptors.

IT 1076054-92-6 1076054-93-7 1076054-95-9
 1076054-96-0 1076054-97-1 1076054-98-2
 1076055-01-0 1076055-02-1 1076055-03-2
 1076055-04-3 1076055-05-4 1076055-06-5
 1076055-07-6 1076055-08-7 1076055-10-1
 1076055-12-3 1076055-13-4 1076055-14-5
 1076055-18-9 1076055-22-5 1076055-24-7
 1076055-28-8 1076055-29-9 1076055-28-1
 1076055-29-2 1076055-30-5 1076055-31-6
 1076055-35-0 1076055-36-1 1076055-37-2
 1076055-39-4


RL: PAPH (Propagetic)
 (Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor
 antagonists)

RN 1076054-92-6 ZCAPLUS


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)
 CN Morpholine, 4-([4-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)



RN 1076054-93-7 ZCAPLUS
 CN Piperazine, 1-([4-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 1076054-95-9 ZCAPLUS
 CN Etanolol, 2-([4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl)methylamino]- (CA INDEX NAME)




RN 1076054-96-0 ZCAPLUS
 CN Piperazine, 1-([4-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076054-97-1 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)




RN 1076054-98-2 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1076055-01-0 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)




RN 1076055-05-4 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)




RN 1076055-06-5 ZCAPLUS
CN Ethanol, 2-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)




RN 1076055-07-6 ZCAPLUS
CN Morphinolone, 4-[[1-(4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076055-02-1 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1076055-03-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)- (CA INDEX NAME)




RN 1076055-04-3 ZCAPLUS
CN Piperazine, 1-cyclopentyl-4-[[1-(4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


RN 1076055-08-7 ZCAPLUS
CN Piperazine, 1-[[1-(4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-10-1 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)




RN 1076055-12-3 ZCAPLUS
CN Morphinolone, 4-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1076055-13-4 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076055-14-5 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1076055-18-9 ZCAPLUS
CN Piperazine, 1-[[3-(2-furanyl)-1-(4-(3-thienyl)phenyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1076055-22-5 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076055-29-2 ZCAPLUS
CN Morphinoline, 4-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1076055-30-5 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-(4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1076055-31-6 ZCAPLUS
CN Ethanol, 2-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)




RN 1076055-24-7 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-25-8 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)- (CA INDEX NAME)




RN 1076055-26-9 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)




RN 1076055-28-1 ZCAPLUS
CN Piperazine, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076055-35-0 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)




RN 1076055-36-1 ZCAPLUS
CN Piperazine, 1-[[1-(4-(1,3-benzodioxol-5-yl)phenyl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1076055-37-2 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1076055-39-4 ZCAPLUS
 CN 3-Pyrrolidinol, 1-([1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl)- (CA INDEX NAME)



IT 774610-86-59
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists)
 RN 774610-86-5 ZCAPLUS
 CN Piperazine, 1-([1-[4-(2-fluoro-1,1'-biphenyl)-4-yl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-methyl- (CA INDEX NAME)



L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN

AN 20041841775 ZCAPLUS
 DN 141:350163
 IT Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists
 IN Schiemann, Kai; Ackermann, Karl-August; Arit, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
 PA Merck Patent GmbH, Germany
 SO Ger. Offen., 102 pp.
 CODEN: GWXBX
 DT Patent
 LA German
 FAR.CTY 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE-----10315572	A1	20041014	2003DE-100015572	20030405 <--
AU-----2004228120	A1	20041021	2004AU-000228120	20040308 <--
CA-----2521201	A1	20041021	2004CA-002521201	20040308 <--
WO-----2004089931	A1	20041021	2004WO-EP0002353	20040308 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MG, SD, SL, SE, TE, UG, ZM, ZW, AM, AG, BY, BG, KG, MD, RU, TJ, TM, AZ, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1626967	A1	20060222	2004EP-000718277	20040308 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CF, EE, HU, PL, SK				
BR-----2004009164	A	20060411	2004BR-000009164	20040308 <--
CN-----1768051	A	20060503	2004CN-080008572	20040308 <--
JP-----2006522035	T	20060928	2006JP-000504584	20040308 <--
US-20060264419	A1	20061123	2005US-000520465	20051005 <--
ZA-----2005008948	A	20070328	2005ZA-000008948	20051104 <--
PRAI 2003DE-100015572	A	20030405 <--		
2004WO-EP0002353	W	20040308 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 141:350163
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R₁ = H, halo, (CH₂)_nHet, etc.; R₂ = (CH₂)_nHet, (CH₂)_nAr, cycloalkyl, etc.; R₃, R₄ = H, (CH₂)_nCO₂H, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted monoarom., bicyclic-heterocycle] and their pharmaceutically acceptable salts were prepared. For example, sodium triacetoxyporonylhydride mediated reductive amination of 1-methyl-piperazine and aldehyde II, e.g., prepared from 2-fluoro-α,γ-dioxo-benzenebutanoic Et ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT_{2A} receptor binding assays, 167-examples of compds. I exhibited IC₅₀ values ranging from 0.015-4.7x10⁻⁷M. Compds. I are claimed suitable as ligands of 5-HT receptors.


IT 1073627-02-7 1073627-03-8 1073627-08-3
 1073627-11-8 1073627-12-9 1073627-14-1
 1073627-15-2 1073627-17-4 1073627-18-5
 1073627-21-0 1073627-22-1 1073627-25-4
 1073627-26-5 1073627-49-2 1073627-74-3
 1073627-75-4 1073628-34-8 1073628-36-0
 1073628-63-3 1073628-64-4 1073629-14-7
 1073629-15-8 1073638-81-9 1073638-82-0
 1073639-09-4 1073639-36-7 1073639-38-9
 1073639-65-2 1073639-66-3 1073639-92-5
 1073639-93-6 1073640-22-8
 1073640-47-7 1073640-48-8 1073640-75-1
 1073640-77-3 1073641-04-9 1073641-05-0
 1073641-30-1 1073641-31-2

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


RL: PRPH (Prophetic)
 (Preparation of arylpyrazoles as serotonin 5-HT_{2A} and 5-HT_{2C} receptor antagonists)
 RN 1073627-02-7 ZCAPLUS
 CN 1H-1,4-Diazepine, 1-([1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)hexahydro- (CA INDEX NAME)



RN 1073627-03-8 ZCAPLUS
 CN 1H-1,4-Diazepine, 1-([1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)hexahydro- (CA INDEX NAME)




RN 1073627-08-3 ZCAPLUS
 CN Piperazine, 1-([1-[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-methyl- (CA INDEX NAME)




RN 1073627-11-8 ZCAPLUS
 CN Piperazine, 1-([1-[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1073627-12-9 ZCAPLUS
 CN Piperazine, 1-[[1-[[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1073627-14-1 ZCAPLUS
 CN 1-Piperazinamine, N-[[[1-[[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-21-0 ZCAPLUS
 CN Morpholine, 4-[2-[1-[[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)




RN 1073627-22-1 ZCAPLUS
 CN Morpholine, 4-[2-[1-[[4'-fluoro[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)




RN 1073627-25-4 ZCAPLUS
 CN Morpholine, 4-[2-[1-[[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 1073627-15-2 ZCAPLUS
 CN 1-Piperazinamine, N-[[[1-[[4'-fluoro[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1073627-17-4 ZCAPLUS
 CN 1-Piperazinamine, N-[[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1073627-18-5 ZCAPLUS
 CN 1-Piperazinamine, N-[[[1-[[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-26-5 ZCAPLUS
 CN Morpholine, 4-[2-[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)




RN 1073627-49-2 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-[[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)




RN 1073627-74-3 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)-1-(6-phenyl-3-pyridinyl)- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-75-4 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1073628-34-8 ZCAPLUS
 CN 1,2-Ethanediamine, N1-([1-[3,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl)methyl)- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073628-36-0 ZCAPLUS
 CN 1,2-Ethanediamine, N1-([1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl)methyl)- (CA INDEX NAME)




RN 1073628-63-3 ZCAPLUS
 CN 1,2-Ethanediamine, N1-([5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl)methyl)- (CA INDEX NAME)




RN 1073628-64-4 ZCAPLUS
 CN 1,2-Ethanediamine, N1-([1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl)methyl)- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073629-14-7 ZCAPLUS
 CN Ethanol, 2-([1-[3,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl)methylamino)- (CA INDEX NAME)




RN 1073629-15-8 ZCAPLUS
 CN Ethanol, 2-([1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl)methylamino)- (CA INDEX NAME)




RN 1073630-81-9 ZCAPLUS
 CN Ethanol, 2-([5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl)methylamino)- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073630-82-0 ZCAPLUS
 CN Ethanol, 2-([1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl)methylamino)- (CA INDEX NAME)




RN 1073630-09-4 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 1073630-36-7 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 5-(2-furanyl)-N-(2-methoxyethyl)-1-(6-phenyl-3-pyridinyl)- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073639-38-9 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-([6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 1073639-65-2 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1073639-66-3 ZCAPLUS
CN Ethanol, 2-[[[1-(1,1'-biphenyl)-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073640-22-8 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1073640-47-7 ZCAPLUS
CN Morpholine, 4-[3-[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)




RN 1073640-48-8 ZCAPLUS
CN Morpholine, 4-[3-[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073639-92-5 ZCAPLUS
CN Ethanol, 2-[[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)




RN 1073639-93-6 ZCAPLUS
CN Ethanol, 2-[[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)




RN 1073640-21-7 ZCAPLUS
CN Morpholine, 4-[3-[1-[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073640-75-1 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[[1-(1,1'-biphenyl)-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1073640-77-3 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[[1-(1,1'-biphenyl)-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1073641-04-9 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1073641-05-0 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl-, (CA INDEX NAME)


L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



IT 774583-85-6P 774585-51-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 774583-85-6 ZCAPLUS
CN Piperazine, 1-[[5-(2-furanyl)-1-[4-(3-thienyl)phenyl]-1H-pyrazol-4-yl]methyl]-4-methyl-, (CA INDEX NAME)



RN 774585-51-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N-cyclopropyl-1-(4'-fluoro[1,1'-biphenyl]-4-yl)-N-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-5-(2-furanyl)- (CA INDEX NAME)




OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)

pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



RN 1073641-30-1 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-, (CA INDEX NAME)



RN 1073641-31-2 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-, (CA INDEX NAME)

CODEN: GWXBX

DT Patent

LA German


FAN.CMI 1

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN

AN 2004:841774 ZCAPLUS
DN 141:332187
TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.
IN Schnadt, Oliver; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 24 pp.
CODEN: GWXBX
DT Patent
LA German
FAN.CMI 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE-----10315571	A1	20041014	2003DE-100015571	20030405 <--
AU--2004228119	A1	20041021	2004AU-000228119	20040308 <--
CA-----2521199	A1	20041021	2004CA-002521199	20040308 <--
WO--2004089888	A1	20041021	2004WO-EP0002352	20040308 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
FW:	BW, GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BF, BG, BR, MD, RU, TJ, TM, AT, BE, BG, CH, CI, CJ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP-----1611094	A1	20060104	2004EP-000718288	20040308 <--
EP-----1611094	B1	20070620		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MW, CY, AL, TR, BG, CL, EE, HU, PL, SK			
BR--2004009160	A	20060502	2004BR-00009160	20040308 <--
CN-----1768053	A	20060503	2004CN-080008604	20040308 <--
JP--2006523626	T	20061019	2006JP-000504583	20040308 <--
AT-----365161	T	20070715	2004AT-000718288	20040308 <--
ES-----2287707	T3	20071216	2004ES-000718288	20040308 <--
US--20060276650	A1	20061207	2005US-000551905	20051005 <--
ZA--2005008946	A	20070228	2005ZA-00008946	20051104 <--
PRAI 2003DE-100015571	A	20030405	<--	
2004WO-EP0002352	W	20040308	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L34US DISPLAY FORMAT
OS MARPAT 141:332187
GI




AB Title compds. [I; R2, R4 = H, A, halo, cycloalkyl, CF3, NO2, cyano, OCF3, OA, NHA, NA2, NH2; R3, R6 = (CH2)nHet, (CH2)nAr; R1 = H, organic residue; A = alkyl, alkoxy, alkenyl, alkenyloxyalkyl; Het = (substituted) (unsatd.) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; Ar = (substituted) Ph; n = 0-5; X undefined], were claimed (no synthetic or biol. data).

IT 1070643-43-4 1070643-44-5 1070643-45-6 1070643-46-7 1070643-47-8 1070643-48-9 1070643-49-0 1070643-50-1 1070643-51-2 1070643-52-3 1070643-53-4 1070643-54-5 1070643-55-6 1070643-56-7 1070643-57-8 1070643-58-9 1070643-59-0 1070643-60-1 1070643-61-2 1070643-62-3 1070643-63-4 1070643-64-5 1070643-65-6 1070643-66-7 1070643-67-8 1070643-68-9 1070643-69-0 1070643-70-1 1070643-71-2 1070643-72-3 1070643-73-4 1070643-74-5 1070643-75-6 1070643-76-7 1070643-77-8 1070643-78-9 1070643-79-0 1070643-80-1 1070643-81-2 1070643-82-3 1070643-83-4 1070643-84-5 1070643-85-6 1070643-86-7 1070643-87-8 1070643-88-9 1070643-89-0 1070643-90-1 1070643-91-2 1070643-92-3 1070643-93-4 1070643-94-5 1070643-95-6 1070643-96-7 1070643-97-8 1070643-98-9 1070643-99-0 1070643-100-1 1070643-101-2 1070643-102-3 1070643-103-4 1070643-104-5 1070643-105-6 1070643-106-7 1070643-107-8 1070643-108-9 1070643-109-0 1070643-110-1 1070643-111-2 1070643-112-3 1070643-113-4 1070643-114-5 1070643-115-6 1070643-116-7 1070643-117-8 1070643-118-9 1070643-119-0 1070643-120-1 1070643-121-2 1070643-122-3 1070643-123-4 1070643-124-5 1070643-125-6 1070643-126-7 1070643-127-8 1070643-128-9 1070643-129-0 1070643-130-1 1070643-131-2 1070643-132-3 1070643-133-4 1070643-134-5 1070643-135-6 1070643-136-7 1070643-137-8 1070643-138-9 1070643-139-0 1070643-140-1 1070643-141-2 1070643-142-3 1070643-143-4 1070643-144-5 1070643-145-6 1070643-146-7 1070643-147-8 1070643-148-9 1070643-149-0 1070643-150-1 1070643-151-2 1070643-152-3 1070643-153-4 1070643-154-5 1070643-155-6 1070643-156-7 1070643-157-8 1070643-158-9 1070643-159-0 1070643-160-1 1070643-161-2 1070643-162-3 1070643-163-4 1070643-164-5 1070643-165-6 1070643-166-7 1070643-167-8 1070643-168-9 1070643-169-0 1070643-170-1 1070643-171-2 1070643-172-3 1070643-173-4 1070643-174-5 1070643-175-6 1070643-176-7 1070643-177-8 1070643-178-9 1070643-179-0 1070643-180-1 1070643-181-2 1070643-182-3 1070643-183-4 1070643-184-5 1070643-185-6 1070643-186-7 1070643-187-8 1070643-188-9 1070643-189-0 1070643-190-1 1070643-191-2 1070643-192-3 1070643-193-4 1070643-194-5 1070643-195-6 1070643-196-7 1070643-197-8 1070643-198-9 1070643-199-0 1070643-200-1 1070643-201-2 1070643-202-3 1070643-203-4 1070643-204-5 1070643-205-6 1070643-206-7 1070643-207-8 1070643-208-9 1070643-209-0 1070643-210-1 1070643-211-2 1070643-212-3 1070643-213-4 1070643-214-5 1070643-215-6 1070643-216-7 1070643-217-8 1070643-218-9 1070643-219-0 1070643-220-1 1070643-221-2 1070643-222-3 1070643-223-4 1070643-224-5 1070643-225-6 1070643-226-7 1070643-227-8 1070643-228-9 1070643-229-0 1070643-230-1 1070643-231-2 1070643-232-3 1070643-233-4 1070643-234-5 1070643-235-6 1070643-236-7 1070643-237-8 1070643-238-9 1070643-239-0 1070643-240-1 1070643-241-2 1070643-242-3 1070643-243-4 1070643-244-5 1070643-245-6 1070643-246-7 1070643-247-8 1070643-248-9 1070643-249-0 1070643-250-1 1070643-251-2 1070643-252-3 1070643-253-4 1070643-254-5 1070643-255-6 1070643-256-7 1070643-257-8 1070643-258-9 1070643-259-0 1070643-260-1 1070643-261-2 1070643-262-3 1070643-263-4 1070643-264-5 1070643-265-6 1070643-266-7 1070643-267-8 1070643-268-9 1070643-269-0 1070643-270-1 1070643-271-2 1070643-272-3 1070643-273-4 1070643-274-5 1070643-275-6 1070643-276-7 1070643-277-8 1070643-278-9 1070643-279-0 1070643-280-1 1070643-281-2 1070643-282-3 1070643-283-4 1070643-284-5 1070643-285-6 1070643-286-7 1070643-287-8 1070643-288-9 1070643-289-0 1070643-290-1 1070643-291-2 1070643-292-3 1070643-293-4 1070643-294-5 1070643-295-6 1070643-296-7 1070643-297-8 1070643-298-9 1070643-299-0 1070643-300-1 1070643-301-2 1070643-302-3 1070643-303-4 1070643-304-5 1070643-305-6 1070643-306-7 1070643-307-8 1070643-308-9 1070643-309-0 1070643-310-1 1070643-311-2 1070643-312-3 1070643-313-4 1070643-314-5 1070643-315-6 1070643-316-7 1070643-317-8 1070643-318-9 1070643-319-0 1070643-320-1 1070643-321-2 1070643-322-3 1070643-323-4 1070643-324-5 1070643-325-6 1070643-326-7 1070643-327-8 1070643-328-9 1070643-329-0 1070643-330-1 1070643-331-2 1070643-332-3 1070643-333-4 1070643-334-5 1070643-335-6 1070643-336-7 1070643-337-8 1070643-338-9 1070643-339-0 1070643-340-1 1070643-341-2 1070643-342-3 1070643-343-4 1070643-344-5 1070643-345-6 1070643-346-7 1070643-347-8 1070643-348-9 1070643-349-0 1070643-350-1 1070643-351-2 1070643-352-3 1070643-353-4 1070643-354-5 1070643-355-6 1070643-356-7 1070643-357-8 1070643-358-9 1070643-359-0 1070643-360-1 1070643-361-2 1070643-362-3 1070643-363-4 1070643-364-5 1070643-365-6 1070643-366-7 1070643-367-8 1070643-368-9 1070643-369-0 1070643-370-1 1070643-371-2 1070643-372-3 1070643-373-4 1070643-374-5 1070643-375-6 1070643-376-7 1070643-377-8 1070643-378-9 1070643-379-0 1070643-380-1 1070643-381-2 1070643-382-3 1070643-383-4 1070643-384-5 1070643-385-6 1070643-386-7 1070643-387-8 1070643-388-9 1070643-389-0 1070643-390-1 1070643-391-2 1070643-392-3 1070643-393-4 1070643-394-5 1070643-395-6 1070643-396-7 1070643-397-8 1070643-398-9 1070643-399-0 1070643-400-1 1070643-401-2 1070643-402-3 1070643-403-4 1070643-404-5 1070643-405-6 1070643-406-7 1070643-407-8 1070643-408-9 1070643-409-0 1070643-410-1 1070643-411-2 1070643-412-3 1070643-413-4 1070643-414-5 1070643-415-6 1070643-416-7 1070643-417-8 1070643-418-9 1070643-419-0 1070643-420-1 1070643-421-2 1070643-422-3 1070643-423-4 1070643-424-5 1070643-425-6 1070643-426-7 1070643-427-8 1070643-428-9 1070643-429-0 1070643-430-1 1070643-431-2 1070643-432-3 1070643-433-4 1070643-434-5 1070643-435-6 1070643-436-7 1070643-437-8 1070643-438-9 1070643-439-0 1070643-440-1 1070643-441-2 1070643-442-3 1070643-443-4 1070643-444-5 1070643-445-6 1070643-446-7 1070643-447-8 1070643-448-9 1070643-449-0 1070643-450-1 1070643-451-2 1070643-452-3 1070643-453-4 1070643-454-5 1070643-455-6 1070643-456-7 1070643-457-8 1070643-458-9 1070643-459-0 1070643-460-1 1070643-461-2 1070643-462-3 1070643-463-4 1070643-464-5 1070643-465-6 1070643-466-7 1070643-467-8 1070643-468-9 1070643-469-0 1070643-470-1 1070643-471-2 1070643-472-3 1070643-473-4 1070643-474-5 1070643-475-6 1070643-476-7 1070643-477-8 1070643-478-9 1070643-479-0 1070643-480-1 1070643-481-2 1070643-482-3 1070643-483-4 1070643-484-5 1070643-485-6 1070643-486-7 1070643-487-8 1070643-488-9 1070643-489-0 1070643-490-1 1070643-491-2 1070643-492-3 1070643-493-4 1070643-494-5 1070643-495-6 1070643-496-7 1070643-497-8 1070643-498-9 1070643-499-0 1070643-500-1 1070643-501-2 1070643-502-3 1070643-503-4 1070643-504-5 1070643-505-6 1070643-506-7 1070643-507-8 1070643-508-9 1070643-509-0 1070643-510-1 1070643-511-2 1070643-512-3 1070643-513-4 1070643-514-5 1070643-515-6 1070643-516-7 1070643-517-8 1070643-518-9 1070643-519-0 1070643-520-1 1070643-521-2 1070643-522-3 1070643-523-4 1070643-524-5 1070643-525-6 1070643-526-7 1070643-527-8 1070643-528-9 1070643-529-0 1070643-530-1 1070643-531-2 1070643-532-3 1070643-533-4 1070643-534-5 1070643-535-6 1070643-536-7 1070643-537-8 1070643-538-9 1070643-539-0 1070643-540-1 1070643-541-2 1070643-542-3 1070643-543-4 1070643-544-5 1070643-545-6 1070643-546-7 1070643-547-8 1070643-548-9 1070643-549-0 1070

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


RN 1070643-43-4 ZCAPLUS

CN Piperazine, 1-ethyl-4-[[5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl]- (CA INDEX NAME)



RN 1070643-44-5 ZCAPLUS


CN 2-Furanmethanamine, N-ethyl-5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-N-methyl- (CA INDEX NAME)



RN 1070643-56-9 ZCAPLUS


CN Piperazine, 1-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)




RN 1070643-57-0 ZCAPLUS

CN Piperazine, 1-ethyl-4-[[3-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1070643-58-1 ZCAPLUS

CN 1H-Pyrazole-4-methanamine, N-ethyl-1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 1070643-59-2 ZCAPLUS

CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


PAGE 1-A



HO

RN 1070643-60-5 ZCAPLUS

CN Piperazine, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)




RN 1070643-61-6 ZCAPLUS

CN 3-Pyrrolidinol, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


PAGE 1-A



HO

RN 1070643-62-7 ZCAPLUS


CN Piperazine, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-ethyl- (CA INDEX NAME)




RN 1070643-63-8 ZCAPLUS

CN 1H-Pyrazole-4-methanamine, 1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-N-ethyl-5-(2-furanyl)-N-methyl- (CA INDEX NAME)


L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1070643-64-9 ZCAPLUS
 CN Piperazine, 1-([1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-methyl- (CA INDEX NAME)




RN 1070643-65-0 ZCAPLUS
 CN Piperazine, 1-ethyl-4-([1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)- (CA INDEX NAME)




RN 1070643-66-1 ZCAPLUS
 CN 3-Pyrrolidinol, 1-([1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)




RN 1070643-69-4 ZCAPLUS
 CN Piperazine, 1-([1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-ethyl- (CA INDEX NAME)




RN 1070643-70-7 ZCAPLUS
 CN 3-Pyrrolidinol, 1-([1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)- (CA INDEX NAME)

PAGE 1-A



L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


PAGE 1-A



HO

PAGE 2-A

RN 1070643-67-2 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, N-ethyl-1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl- (CA INDEX NAME)




RN 1070643-68-3 ZCAPLUS
 CN Piperazine, 1-([1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


PAGE 2-A

HO


RN 1070643-71-8 ZCAPLUS
 CN Piperazine, 1-([1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)- (CA INDEX NAME)



RN 1070643-72-9 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N,N-dimethyl- (CA INDEX NAME)




RN 1070643-73-0 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl- (CA INDEX NAME)



RN 1070643-74-1 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)


PAGE 1-A



PAGE 2-A




RN 1070643-75-2 ZCAPLUS
 CN Piperazine, 1-([1-(2,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl)-4-methyl- (CA INDEX NAME)




RN 1070643-76-3 ZCAPLUS
 CN 1H-Pyrazole-4-methanamine, 1-(2,4'-difluoro[1,1'-biphenyl]-4-yl)-N-ethyl-5-(2-furanyl)-N-methyl- (CA INDEX NAME)


L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



RN 1070643-80-9 ZCAPLUS
 CN Piperazine, 1-([5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl)-4-methyl- (CA INDEX NAME)



RN 1070643-81-0 ZCAPLUS
 CN 3-Pyrrolidinol, 1-([5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN

AN 2004:40643 ZCAPLUS

DN 140:391231

TI Novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolopyrazoline derivatives as anti-inflammatory agents

AU Masr, Magda H. A.; Said, Shenta A.

CS Department of Pharmaceutical Organic Chemistry, College of Pharmacy, University of Mansoura, Mansoura, Egypt
 SO Archiv der Pharmazie (Weinheim, Germany) (2003), 336(12), 551-559

CODEN: ARPMAS; ISSN: 0365-6233

PB Wiley-VCH Verlag GmbH & Co. KGaA

DI Journal

LA English


OS CASREACT 140:391231

AB A novel series of 7-benzylidene-3,3a,4,5,6,7-hexahydro-3-phenyl-2H-indazole substituted at the 2-position were synthesized. The reaction of 2,6-bis-benzylidenecyclohexanone (1) with thiosemicarbazide in the presence of NaOH afforded a mixture of the 3-H, 3a-H trans (2) and cis (2a) diastereoisomers which have been separated by fractional recrystn. Interaction of the first intermediate (2) with substituted phenacyl bromides, aromatic aldehydes and chloroacetic acid in presence of a mixture of acetic acid and acetic anhydride, and 2,3-dichloroquinoxaline yielded the corresponding 7-benzylidene-3,3a,4,5,6,7-hexahydro-3-phenyl-2H-indazole derivs. substituted at the 2-position with 4-aryl-2-thiazolyl (3a, b), 5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl (4a, b) and thiazolo[4,5-b]quinoxalin-2-yl (5), resp. The other intermediates, 3,5-diaryl-1-thiocarbamoyl-2-pyrazolines (7a-d), interacted with the previously-mentioned reagents to produce 3,5-diaryl-1-(4-aryl-2-thiazolyl)-2-pyrazolines (8a-h), 3,5-diaryl-1-(5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl)-2-pyrazolines (9a-d) and 3,5-diaryl-1-(thiazolo[4,5-b]quinoxalin-2-yl)-2-pyrazoline derivs. (10a, b), resp. Some of the newly prepared compds. were evaluated for their anti-inflammatory activity. The structures of the new compds. were confirmed by elemental anal. as well as IR-NMR, IR, and MS.


II 686725-88-2P 686725-92-8P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolopyrazoline derivs. as anti-inflammatory agents)

RN 686725-88-2 ZCAPLUS
 CN Thiazole, 4-(4-chlorophenyl)-2-[3-(4-chlorophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 686725-92-8 ZCAPLUS
 CN Thiazole, 4-(4-chlorophenyl)-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




II 686726-02-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolopyrazoline derivs. as anti-inflammatory agents)


RN 686726-02-3 ZCAPLUS
 CN 4-(5H)-Thiazole, 5-[(4-chlorophenyl)methylene]-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




II 686725-82-6P 686725-84-8P 686725-86-0P

686725-90-6P 686725-98-4P 686726-00-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolopyrazoline derivs. as anti-inflammatory agents)

RN 686725-82-6 ZCAPLUS
 CN Thiazole, 4-(4-bromophenyl)-2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 686725-84-8 ZCAPLUS
 CN Thiazole, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 686725-86-0 ZCAPLUS
 CN Thiazole, 4-(4-bromophenyl)-2-[3-(4-chlorophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)


L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 686725-90-6 ZCAPLUS
 CN Thiazole, 4-[(4-bromophenyl)-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 686725-98-4 ZCAPLUS
 CN 4(5H)-Thiazolone, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-5-[(4-bromophenyl)methylene]- (CA INDEX NAME)



RN 686726-00-1 ZCAPLUS
 CN 4(5H)-Thiazolone, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-5-[(4-chlorophenyl)methylene]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 6 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:971725 ZCAPLUS
 DN 140:35893
 TI Transcription factor modulating compounds and methods of use thereof
 IN Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohmeneg, Kwasi;
 Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena
 PA USA
 SO U.S. Pat. Appl. Publ., 301 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20030229065	A1	20031211	2002US-000139591	20020814 <--
CA-----2445515	A1	20021104	2002CA-002445515	20020506 <--
WO-2004001058	A2	20031231	2002WO-US0014255	20020506 <--
WO-2004001058	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU-2002367953	A1	20040106	2002AU-000367953	20020506 <--
AU-2002367953	B2	20080717		
EP-----1524974	A2	20050427	2002EP-000807554	20020506 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP-2005519998	I	20050707	2004JP-000515557	20020506 <--
US-20050124678	A1	20050609	2003US-000700461	20031103 <--
US-----7405235	B2	20080729		
US-20090131401	A1	20090521	2008US-000069723	20080212 <--
AU-20080203017	A1	20080731	2008AU-000203017	20080708 <--
PRAI 2001US-0288660P	P	20010504	<--	
2002AU-000367953	A3	20020506	<--	
2002WO-US0014255	W	20020506	<--	
2002US-000139591	A2	20020814	<--	
2002US-00423319P	P	20021101	<--	
2002US-00425916P	P	20021113	<--	
2003US-000700461	A3	20031103	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

MARPAT 140:35893

AB Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: (1) a selectable marker under the control of a transcription factor responsive element and (2) a transcription factor, with a compound under conditions which allow interaction of the compound with the microbial cell; and measuring the ability of the compound to affect the growth or survival of the microbial cell as an indication of whether the test compound modulates the activity of a transcription factor.

II 634189-97-2

RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)

RN 634189-97-2 ZCAPLUS

CN Morpholine, 4-[(4-[2-[5-(2-furanyl)-4,5-dihydro-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-4-thiazolyl]phenyl)sulfonyl]-, hydrobromide (1:1) (CA INDEX NAME)

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HBr


OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2003:30107 ZCAPLUS
 DN 138:304309
 TI Preparation of 2-(heterocyclalalkyl)-1,2,3,4-tetrahydroquinolines and
 analogs as 5-HT1A receptor inhibitors for treatment of urinary tract
 disorders
 IN Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Testa, Rodolfo; Corbett,
 Jeff W.
 PA Recordati S.A., Switz.; Recordati Industria Chimica e Farmaceutica S.p.A.
 SO PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PI	WO	NO	KIND	DATE	APPLICATION NO.	DATE
WO	2003031436	A1	20030417	2002WO-EP0011282	20021007	<--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TE, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
IT	2001MI2060	A1	20030407	2001IT-MI0002060	20011005	<--
CA	2458456	A1	20030417	2002CA-02458456	20021007	<--
AU	2002346979	A1	20030422	2002AU-00346979	20021007	<--
AU	2002346979	B2	20050929			
AU	2002346979	B9	20060302			
US	20030162777	A1	20030828	2002US-000266104	20021007	<--
US	20030181446	A1	20030925	2002US-000266088	20021007	<--
EP	1432701	A1	20040630	2002EP-000782863	20021007	<--
EP	1432701	B1	20051221			
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR	2002013067	A	20040928	2002BR-000013067	20021007	<--
HU	2004001598	A2	20041228	2004HU-000001598	20021007	<--
CN	20050112	A	20050112	2002CN-000819728	20021007	<--
JP	200508952	T	20050407	2003JP-000534419	20021007	<--
NE	522511	A	20051028	2002NE-000532511	20021007	<--
AT	313540	T	20060115	2002AT-000782863	20021007	<--
ES	2253568	T3	20060601	2002ES-000782863	20021007	<--
AP	1705	A	20070228	2004AP-000002997	20021007	<--
IN	200400392	A	20060414	2004IN-000000392	20040324	<--
MX	2004002962	A	20050620	2004MX-000002962	20040330	<--
NO	2004001833	A	20040705	2004NO-000001833	20040504	<--
ZA	2004003356	A	20041108	2004ZA-000003356	20040504	<--
HK	1067362	A1	20060804	2004HK-000107812	20041011	<--
PRAI	2001IT-MI0002060	A	20011005	<--		
2002US-003064809	P	20020122	<--			
2002WO-EP0011282	W	20021007	<--			



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L5US DISPLAY FORMAT
 OS MARPAT 138:304309
 GI

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN (Continued)



AB Title compds. I [wherein R1 = H, halo, OH, (halo)alkyl, (halo)alkoxy, NO2, NR3R4, or (un)substituted Ph or heterocyclyl; R2 = 1 or 2 substituents selected from H or alkyl; R3 and R4 = independently H, alkyl, acyl, or alkoxycarbonyl; Y = a bond or CH2; Q = CO, CS, or SO2; A = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, aryl, heterocyclyl, (di)alkylamino, arylamino, or arylalkylamino; n = 1 or 2; X = (un)substituted piperidinyl or piperazinyl; Z = a bond, O, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO, or NHCONHCH2; or ZB = 2,3-dihydrobenzo[1,4]dioxin-2-yl; B = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos; and enantiomers, diastereomers, N-oxides, crystalline forms, hydrates, or pharmaceutically acceptable salts thereof] were prepared as serotonergic receptor antagonists. For example, coupling of 2-chloromethylquinoline with 1-(4-indolyl)piperazine in the presence of DIPEA in DMF gave 1-(4-indolyl)-4-(quinolin-2-ylmethyl)piperazine (70%), which was hydrogenated using PtO2/AcOH/H2 to provide the tetrahydroquinoline derivative (76.5%). Amidation with cyclohexanecarbonyl chloride in the presence of TEA in CH2Cl2 afforded II (81%). The (+)- and (-)-enantiomers were separated via chiral column chromatog. II inhibited the human 5HT1A-serotonergic receptor in transfected HeLa cells with Ki of 3.3 nM, while (+)-II showed a binding affinity with Ki of 0.2 nM. Similarly, (+)-II proved more effective than II in suppressing the frequency of rhythmic bladder-voiding contractions in rats with ED50 values of 24 µg/kg and 64 µg/kg, resp. In addition, (+)-II exhibited significant and long-lasting post-synaptic 5-HT1A-receptor antagonist activity by suppressing forepaw treading induced by 8-OH-DPAT in rats with 100% inhibition after 0.5 h and 98% inhibition after 4 h of administration of a dose of 1 mg/kg p.o. By contrast, (-)-II showed only 19% inhibition after 0.5 h and 5% inhibition after 4 h of administration of a dose of 1 mg/kg p.o.

II 511233-54-8P 1-[1-(Cyclohexylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-ylmethyl]-4-[(5-(2-furyl)-2H-3-pyrazolyl)piperidine] (CA INDEX NAME)


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT1A antagonist; preparation of (aminoalkyl)- and (heterocyclalalkyl)tetrahydroquinoline 5-HT1A antagonists from haloalkylquinolines and amines or heterocycles for treatment of urinary tract and CNS disorders)

511233-54-8 ZCAPLUS
 CN Methanone, cyclohexyl[2-[(4-[(5-(2-furyl)-1H-pyrazol-1-yl)-1-piperidinyl)methyl]-3,4-dihydro-1(2H)-quinolinyl]- (CA INDEX NAME)

L34 ANSWER 8 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN

AN 2002:438220 ZCAPLUS
 DN 137:384785
 TI The regioselectivity of the formation of 2-pyrazolylthiazoles and their precursors from the reaction of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones
 AU Denisova, Anna B.; Sosnovskikh, Vyacheslav Ya.; Dehaen, Wim; Toppet, Suzanne; Van Meerelt, Luc; Bakulev, Vasily A.
 CS Toslab, The Urals State Technical University, Yekaterinburg, 620002, Russia
 SO Journal of Fluorine Chemistry (2002), 115(2), 183-192
 CODEN: JFLICAR; ISSN: 0022-1139
 DT Elsevier Science B.V.
 LA Journal
 OS English
 OS CASREACT 137:384785
 GI




AB Reaction of 2-hydrazinothiazoles with 1-thienyl- and 1-furyl-1,3-butanediones in methanol in the presence of hydrochloric acid mainly leads to a mixture of pyrazoles and pyrazolines in strong acidic conditions. Isomeric hydrazones and pyrazolines were formed and isolated in these reactions in the absence of hydrochloric acid. It has been shown that the regioselectivity in the reaction of diketones with 2-hydrazinothiazoles is governed by both the concentration of acid and the nature of substituents in the 1,3-diketones. Cyclization of hydrazones is shown to occur under milder conditions than dehydration for pyrazolines. The new heterocyclic compds. were prepared and fully characterized by NMR spectra and by X-ray anal. for I.


II 476172-22-2P 476172-23-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(regioselective preparation of 2-pyrazolylthiazoles from the condensation of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones)

RN 476172-22-2 ZCAPLUS
 CN 1H-Pyrazol-5-ol, 1-(4-(4-chlorophenyl)-2-thiazolyl)-3-(2-(2-furyl)-4,5-dihydro-5-(trifluoromethyl)- (CA INDEX NAME)




RN 476172-23-3 ZCAPLUS
 CN 1H-Pyrazol-5-ol, 3-(2-(2-furyl)-4,5-dihydro-1-(4-phenyl-2-thiazolyl)-5-(trifluoromethyl)- (CA INDEX NAME)




L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 IT 476172-15-3P 476172-16-4P 476172-28-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective preparation of 2-pyrazolylthiazoles from the condensation of
 2-hydrazinethiazoles with 4,4,4-trifluoro-1-betaryl-1,3-butanediones)
 RN 476172-15-3 ZCAPLUS
 CN Thiazole, 4-(4-chlorophenyl)-2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-
 pyrazol-1-yl]- (CA INDEX NAME)




RN 476172-16-4 ZCAPLUS
 CN Thiazole, 2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-phenyl-
 (CA INDEX NAME)



RN 476172-28-8 ZCAPLUS
 CN Thiazole, 4-(4-chlorophenyl)-2-[3-(2-furanyl)-5-(trifluoromethyl)-1H-
 pyrazol-1-yl]- (CA INDEX NAME)



RN 476172-31-3 ZCAPLUS
 CN Thiazole, 2-[3-(2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]-4-phenyl-
 (CA INDEX NAME)




OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
 RN 1992:625143 ZCAPLUS
 DN 117:225143
 OREF 117:38659a,38662a


TI Studies on the complexes of rare earths with sulfur-containing organic
 ligands. IV. Synthesis and characterization of solid complexes of light
 rare earths with 3-phenyl-5-(fur-2-yl)pyrazolinedithioformate
 AU Zhang, Weiguang; Tang, Ning; Gan, Ximin; Tan, Minyu
 CS Dep. Chem., Jiangxi Norm. Univ., Peop. Rep. China
 SO Yingyong Huaxue (1992), 9(3), 83-6
 CODEN: YIHUED; ISSN: 1000-0518
 DT Journal
 LA Chinese
 AB LnL3.nH2O (Ln = La, Pr, Nd, Sm, Eu; HL =
 3-phenyl-5-(fur-2-yl)pyrazolinedithioformic acid; n = 2, 4) were prepared
 and characterized by elemental anal., IR spectra, molar conductance,
 thermal anal. and fluorescence spectra. L is coordinated through the 2 S
 atoms.

IT 144395-32-4P 144395-34-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and IR spectrum of)
 RN 144395-32-4 ZCAPLUS
 CN Lanthanum, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-
 carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)




RN 144395-34-6 ZCAPLUS
 CN Neodymium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-
 carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)

L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 144395-33-5P 144395-35-7P 144423-48-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and fluorescence and IR spectra of)
 RN 144395-33-5 ZCAPLUS
 CN Praseodymium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-
 carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)




RN 144395-35-7 ZCAPLUS
 CN Samarium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-
 carbodithioato-S,S']-, dihydrate, (OC-6-11)- (9CI) (CA INDEX NAME)


L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 144423-48-3 ZCAPLUS
 CN Europium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-
 carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)



L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS ON STN
AN 1985:6328 ZCAPLUS
DN 102:6328
ORF 102:11474,1150a
I1 Syntheses and biological activity of heterocycles derived from
4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]benzoic acid;
V K. K. S.; Fernandez, P. S.
CU Dep. Chem., St. Xavier's Coll., Bombay, 600 013, India
SO Journal of the Indian Chemical Society (1984), 61(3), 234-6
DN CODEN: JICSHN; ISSN: 0019-4522
Journal
LA English
OS CASREACT 102:6328
GI




AB A series of new compds. I (R = CO₂H, CONHNH₂, CONHN:CH₂l, CONHNH₂SNHC₆H₄R-4, R₃, R₄; R₁ = Ph, 4-MeC₆H₄, 2-HOC₆H₄, 4-MeOC₆H₄, 2-furyl; R₂ = H, Me, Cl, OMe) have been synthesized and some of the compds. have been screened against a few microorganisms for antibacterial activity.

IT	93606-89-4F	93606-90-7F	93606-91-8F
	93606-92-9F	93606-93-0F	93606-94-1F
	93606-95-2F	93606-96-3F	


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

3H-1,2,4-Triazole-3-thione, 5-[4-(5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl)phenyl]-2,4-dihydro-4-phenyl- (CA INDEX NAME)




RN 93606-90-7 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro-4-(4-methylphenyl)- (CA INDEX NAME)


L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 93606-91-8 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 4-(4-chlorophenyl)-5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro- (CA INDEX NAME)



RN 93606-92-9 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 93606-93-0 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-phenyl- (CA INDEX NAME)




RN 93606-94-1 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(4-methylphenyl)- (CA INDEX NAME)


L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 93606-95-2 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, N-(4-chlorophenyl)-5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]- (CA INDEX NAME)



RN 93606-96-3 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(4-methoxyphenyl)- (CA INDEX NAME)





L34 ANSWER 11 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN

AN 1977:105229 ZCAPLUS
DN 86:105229
OREF 86:16597a.16600a
TI Electrochemical behavior of N-aryl- Δ^2 -pyrazolines. IX. Structure effects in the spectra of radical cations and dications of monomers and dimers of N-aryl- Δ^2 -pyrazolines and mechanism of the Knorr-pyrazoline test

AU Pragst, F.; Vieth, B.
CS Sekt. Chem., Humboldt-Univ. Berlin, Berlin, Ger. Dem. Rep.
SO Zeitschrift fuer Physikalische Chemie (Leipzig) (1976), 257(5),
240-62


849-87
CODEN: ZPCLAH; ISSN: 0323-4479
DT Journal
LA German

GI




AB A bathochromic shift of the first UV bond for cation radicals of I (R = H, MeO, Me, Ph, Cl, NO₂; R₁, R₂ = aryl, alkyl) was rationalized in terms of electronic and steric effects. The cation radicals of II, III (R₁, R₂ as above), and IV are violene types and absorb at very long wavelengths. Oxidation of I by FeCl₃ or NaNO₂ in concentrated H₂SO₄ yields dications of the corresponding dimers (II) in agreement with electrochem. oxidation data.

IT 61979-54-2 61987-61-9
 RL: PRP (Properties)
 (UV spectrum of)
 RN 61979-54-2 ZCAPLUS
 CN 1H-Pyrazolium, 5-(2-furanyl)-1-[4-{4-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazolium-1-ylidene]-2,5-cyclohexadien-1-ylidene]-2,5-cyclohexadien-1-ylidene)-4,5-dihydro-3-(4-methylphenyl)- (CA INDEX NAME)



RN 61987-61-9 ZCAPLUS
CN 1H-Pyrazole, 1,1'-(1,1'-biphenyl)-4,4'-diylbis[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-, radical ion(1+)] (9CI) (CA INDEX NAME)

L34 ANSWER 11 OF 13 SCAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L34 ANSWER 12 OF 13 SCAPLUS COPYRIGHT 2010 ACS on STN

AN 1975:461730 SCAPLUS
 DN 83:61730
 OREF 83:9753a,9756a
 TI 4-(3-Aryl-1-pyrazolyl)stilbene fluorescent whiteners
 IN Haeusermann, Heinrich; Trokler, Eduard
 PA Ciba-Geigy Corp.
 SO U.S., 9 pp.
 CODEN: USKXAM
 DT Patent
 LA English
 FAR CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-----3796706	A	19740312	1970US-000065699	19700820 <--
PRAI 1968US-000703865	A2	19680208		


GI For diagram(s), see printed CA Issue.
 AB Fluorescent whiteners (I, R = Cl, 3-(2-furyl)-1-pyrazolyl, substituted triazinylamino, substituted stilbenylureido; R3 = H, SO3H; R2 = SO3H CN; R3 = Ph, p-ClC6H4, R4 = H, or (R3R4) = o-C6H4CH2CH2) were prepared and were used to whiten cellulosic, acetate, polyester, and polyamide fibers and in detergent compns. Thus, 2,4-HO3S(H2NNH)C6H3CH:CHC6H3(NHNH2)SO3H-4,2 in an aqueous NaOH solution was treated with 2-furyl 2-chlorovinyl ketone to give fluorescent whitener I(R = 3-(2-furyl)-1-pyrazolyl, R1 = R2 = SO3Na, R3 = 2-furyl, R4 = H). The other I were similarly prepared
 II 51837-62-0P
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (preparation of)
 RN 51837-62-0 SCAPLUS
 CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[3-(2-furanyl)-1H-pyrazol-1-yl]-, disodium salt (9CI) (CA INDEX NAME)




● 2 Na

L34 ANSWER 13 OF 13 SCAPLUS COPYRIGHT 2010 ACS on STN

AN 1969:115058 SCAPLUS
 DN 70:115058
 OREF 70:21487a,21490a
 TI Fluorinated nitrogen heterocycles via cyclization. III. 3-Trifluoromethyl-1-(4-(trifluoromethyl-2-pyridyl)pyrazoles from fluorinated 1,3-diketones and 4-(trifluoromethyl-2-hydrazinopyridines
 AU Portnoy, Seymour
 CS Frankford Arsenal, Philadelphia, PA, USA
 SO Journal of Heterocyclic Chemistry (1969), 6(2), 223-8
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB Fluorinated 1,3-diketone CF3COCH2COR1 underwent cyclization with 4-(trifluoromethyl-2-hydrazinopyridines (I) to give a series of 3-trifluoromethyl-1-(4-(trifluoromethyl-2-pyridyl)pyrazoles (II). I were prepared by conversion of 4-(trifluoromethyl-2-pyridones to the chloropyridines followed by treatment of the latter with hydrazine hydrate.
 IT 22122-94-7p 22123-05-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 22122-94-7 SCAPLUS
 CN 1H-Pyrazol-5-ol, 3-(2-furanyl)-4,5-dihydro-1-[6-(2-thienyl)-4-(trifluoromethyl)-2-pyridinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 22123-05-3 SCAPLUS
 CN Pyridine, 2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-6-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

=> d his

FILE 'ZCAPLUS' ENTERED AT 12:29:38 ON 05 FEB 2010
 L1 1 US20070010531/PN

FILE 'REGISTRY' ENTERED AT 12:29:58 ON 05 FEB 2010

FILE 'ZCAPLUS' ENTERED AT 12:29:58 ON 05 FEB 2010
 L2 TRA L1 1- RN : 678 TERMS

FILE 'REGISTRY' ENTERED AT 12:29:58 ON 05 FEB 2010
 L3 678 SEA L2
 L4 674 L3 AND N2C3/ES
 L5 206 L4 AND OC4/ES
 L6 206 L5 AND (C6 OR NC5)/ES
 L7 STR
 L8 59880 OC4/ES AND N2C3/ES AND (C6 OR NC5)/ES
 L9 50 L7 SAM SUB=L8
 L10 10904 L7 FULL SUB=L8
 SAV TEM J064C1RCE/A L10
 L11 205 L10 AND L3
 L12 10699 L10 NOT L11

FILE 'ZCAPLUS' ENTERED AT 12:35:47 ON 05 FEB 2010
 L13 2 L11
 L14 698 L12
 L15 164 L14 AND (PRD<=20040410 OR AD<=20040410)
 L16 456 L14 AND PD<=20030405
 L17 422 L14 AND PD<=20020405
 L18 126 L15 AND L16-17
 L19 330 L16 NOT L18
 L20 314 L17 NOT L18
 L21 38 L15 NOT L18
 SEL HIT RN L21

FILE 'REGISTRY' ENTERED AT 12:41:40 ON 05 FEB 2010
 L22 193 E1-193
 L23 STR L7
 L24 29 L23 SAM SUB=L10
 L25 496 L23 FULL SUB=L10
 SAV TEM J064C1RCES/A L25
 L26 204 L25 AND L3
 L27 292 L25 NOT L26

FILE 'ZCAPLUS' ENTERED AT 13:01:30 ON 05 FEB 2010
 L28 2 L26
 L29 2 L13,L28
 L30 25 L27
 L31 7 L30 AND (PRD<=20040410 OR AD<=20040410)
 L32 9 L30 AND PD<=20030405
 L33 6 L30 AND PD<=20020405
 L34 13 L31-33

=>